If your trial fails to meet its Phase II or Phase III endpoints, you can be faced with difficult choices. Either abandoning or deprioritizing the product. Both of these options have significant consequences for your business and the patients you strive to help.
Today, advanced analytics such as machine learning are enabling new, more precise views into the data, identifying predictive biomarkers and generating sub-groups based on characteristics that might yield different results.
Capturing this data can be the difference between a successful trial and a discarded product.
IQVIA's Sub-Population Optimization solution identfies sub-populations from your trial data where the treatment effect is more pronounced, avoiding both bias an statistical type-1 errors. This can support
A customized solution built around your molecule and patient population
The power of the IQVIA CORE integrates your data with IQVIA's advanced analytics, technology and domain expertise to develop purpose-built algorithms that identify patterns with greater precision.
Powered by the CORE, IQVIA's advanced statisticians can suggest enhanced study designs or new development strategies by finding patterns and connections in trial results.
Our team also ensures that data and parameters are consistent with industry standards and best practice, so you can decide with confidence how to move forward.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Build and compare potential pipeline development strategies quickly and transparently.
Capture the patient experience across the full trial process, from strategy to dissemination of results.